HUMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HUMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Humacyte's annualized ROCE % for the quarter that ended in Mar. 2024 was -93.58%.
The historical data trend for Humacyte's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humacyte Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
ROCE % | -67.38 | -11.93 | -2.51 | -70.75 |
Humacyte Quarterly Data | |||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROCE % | Get a 7-Day Free Trial | -82.00 | -53.14 | -67.45 | -76.64 | -93.58 |
Humacyte's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -104.177 | / | ( ( (204.302 - 19.58) | + | (128.223 - 18.443) ) | / 2 ) | |
= | -104.177 | / | ( (184.722 | + | 109.78) | / 2 ) | |
= | -104.177 | / | 147.251 | ||||
= | -70.75 % |
Humacyte's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -120.32 | / | ( ( (128.223 - 18.443) | + | (161.466 - 14.087) ) | / 2 ) | |
= | -120.32 | / | ( ( 109.78 | + | 147.379 ) | / 2 ) | |
= | -120.32 | / | 128.5795 | ||||
= | -93.58 % |
(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humacyte (NAS:HUMA) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Humacyte's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Laura E Niklason | director, 10 percent owner, officer: President, CEO and Director | 35 WILSHIRE ROAD, GREENWICH CT 06831 |
Brady W Dougan | director, 10 percent owner | 35 WILSHIRE ROAD, GREENWICH CT 06831 |
Ayabudge Llc | 10 percent owner | 35 WILSHIRE ROAD, GREENWICH CT 06831 |
Heather Ledbetter Prichard | officer: Chief Operating Officer | 820 BROWNWICH STREET, WAKE FOREST NC 27587 |
Michael T. Constantino | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Dale A. Sander | officer: CFO & CCDO | 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617 |
William John Scheessele | officer: Chief Commercial Officer | 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605 |
Yang Cao | officer: Chief Regulatory Officer | 12 DOGLEG LANE, LAWRENCE NJ 08648 |
Charles Bruce Green | director | 3185 SCENIC DRIVE, NAPA CA 94558 |
Gordon M Binder | director | 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101 |
Diane Seimetz | director | JUTASTRASSE, MUNICH 2M 80636 |
Shamik J Parikh | officer: Chief Medical Officer | 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060 |
Rajiv Shukla | director | EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411 |
William Edward Tente | officer: Chief Regulatory Officer | 90 DAVIS STREET, SEEKONK MA 02771 |
Todd Pope | director | C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713 |
From GuruFocus
By Marketwired • 09-18-2023
By Marketwired • 08-03-2023
By Marketwired • 09-11-2023
By sperokesalga sperokesalga • 03-21-2023
By sperokesalga sperokesalga • 04-18-2023
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 08-14-2023
By Marketwired • 09-11-2023
By Stock market mentor Stock market mentor • 01-24-2023
By sperokesalga sperokesalga • 05-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.